For more than a year, Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema. On Friday, Novo released the results of a large Phase 3 trial of the drug. Patients lost only 22.7% of their body weight, on average, after about a year and a half.